CD19 and diffuse large B-cell lymphoma: As previously mentioned, the FDA has recently approved the CD19 CAR-T cell approach from Novartis, Kymriah®, to treat patients with B cell ALL and the CD19 CAR-T cell approach from Kite Pharma, YESCARTATM, for the treatment of diffuse large B-cell lymphoma.